Cargando…

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer

PURPOSE: Evaluating consecutive early breast cancer patients, we analyzed both the impact of EndoPredict(®) on clinical decisions as well as clinico-pathological factors influencing the decision to perform this gene expression test. METHODS: Hormone receptor (HR)-positive and human epidermal growth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Almstedt, K., Mendoza, S., Otto, M., Battista, M. J., Steetskamp, J., Heimes, A. S., Krajnak, S., Poplawski, A., Gerhold-Ay, A., Hasenburg, A., Denkert, C., Schmidt, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275019/ https://www.ncbi.nlm.nih.gov/pubmed/32436145 http://dx.doi.org/10.1007/s10549-020-05688-1

Ejemplares similares

Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study
por: Krajnak, S., et al.
Publicado: (2020)

Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients
por: Nezi-Cahn, Sandra, et al.
Publicado: (2019)

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
por: Martin, Miguel, et al.
Publicado: (2016)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions
por: Müller, Berit Maria, et al.
Publicado: (2013)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
por: Dubsky, P, et al.
Publicado: (2013)

Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay
por: Denkert, Carsten, et al.
Publicado: (2012)

Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population
por: Schmidt, Marcus, et al.
Publicado: (2018)

Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
por: Constantinidou, Anastasia, et al.
Publicado: (2022)

Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
por: Dubsky, P., et al.
Publicado: (2013)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

Prognostic Impact of CD38- and IgκC-Positive Tumor-Infiltrating Plasma Cells in Triple-Negative Breast Cancer
por: Heimes, Anne-Sophie, et al.
Publicado: (2023)

Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections
por: Müller, Berit Maria, et al.
Publicado: (2012)

Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

Real-World Experience of Metronomic Chemotherapy in Metastatic Breast Cancer: Results of a Retrospective Unicenter Study
por: Krajnak, Slavomir, et al.
Publicado: (2023)

Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer
por: Almstedt, Katrin, et al.
Publicado: (2023)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer
por: Bösl, Andreas, et al.
Publicado: (2017)

Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes
por: Heimes, Anne-Sophie, et al.
Publicado: (2020)

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value
por: Chow, Louis W C, et al.
Publicado: (2017)

Individualized Chemotherapy Benefit Prediction by EndoPredict in Patients With Early Breast Cancer in an Indian Cohort
por: Somashekhar, S. P., et al.
Publicado: (2020)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
por: Jank, Paul, et al.
Publicado: (2021)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial
por: Martin, Miguel, et al.
Publicado: (2014)

Prognostic Impact of LAG-3 mRNA Expression in Early Breast Cancer
por: Heimes, Anne-Sophie, et al.
Publicado: (2022)

Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results
por: Noske, Aurelia, et al.
Publicado: (2019)

Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint
por: Amezcua-Gálvez, Jesús Eduardo, et al.
Publicado: (2022)

Prognostic Impact of Immunoglobulin Kappa C (IGKC) in Early Breast Cancer
por: Schmidt, Marcus, et al.
Publicado: (2021)

The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry
por: Meegdes, Marissa, et al.
Publicado: (2022)

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells
por: Krajnak, Slavomir, et al.
Publicado: (2023)

Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests
por: Jahn, Stephan Wenzel, et al.
Publicado: (2020)

Change in therapeutic management after the EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2020)

Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test
por: Kronenwett, Ralf, et al.
Publicado: (2012)

Vasa previa: A rare obstetric complication–A case series and a literature review
por: Degirmenci, Yaman, et al.
Publicado: (2022)

Current Approaches to the Management of Sentinel Node Procedures in Early Vulvar Cancer in Germany: A Web-Based Nationwide Analysis of Practices
por: Schwab, Roxana, et al.
Publicado: (2023)

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial
por: Fitzal, F, et al.
Publicado: (2015)

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study
por: Lynce, F., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_udvtu0h0eia23gnmkfmq0h86gk